ArticleBMC genomics2026
Comparative study on the expression levels of antithrombotic genes in five sympatrically distributed leech species.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Medicinal leeches are rich in various antithrombotic components, holding significant pharmaceutical value. To investigate the differences in potential antithrombotic capacity among species, this study utilized transcriptome sequencing technology to compare the expression differences of antithrombotic-related genes in five sympatrically distributed leech species (Whitmania pigra, Whitmania laevis, Whitmania acranulata, Hirudo nipponia, and Hirudo tianjinensis). The results revealed significant differences in the overall expression levels of antithrombotic genes among different species. Most samples clustered by species in the cluster analysis, indicating that the expression patterns of these genes are highly species-specific. Analysis of antithrombotic gene functional groups (coagulation inhibitor, platelet aggregation inhibitor, fibrinolysis enhancer, anti-inflammatory agents, and tissue penetration enhancer) showed that, except for W. laevis, the other four species exhibited the highest total expression in the coagulation inhibitor group. Among them, W. pigra, W. acranulata, and H. nipponia had a significantly greater number of dominantly expressed functional groups (N ≥ 2) compared to W. laevis and H. tianjinensis (N = 1). Gene family comparisons revealed that the number of dominantly expressed gene families in W. pigra, W. acranulata, and H. nipponia was significantly higher than that in W. laevis and H. tianjinensis. Additionally, 28 highly expressed key antithrombotic genes were identified across the five species, with the vast majority of these genes accounting for over 50% of the total expression within their respective gene families. According to the above results, we speculate that W. pigra, W. acranulata, and H. nipponia exhibit higher potential antithrombotic capacity at the transcriptional level. These molecular traits align, at least in part, with the empirical wisdom accumulated through centuries of traditional Chinese medicine practice regarding the therapeutic value of specific leech species, although further rigorous pharmacological validation is required to substantiate our hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.